Gaeta GM, Satriano RA, Baroni A
The first incretin-based drug approved specifically for weight loss was liraglutide (Saxenda), developed by Novo Nordisk
It also suppresses pro-inflammatory cytokines, reducing inflammation by regulating multiple cellular pathways, which is a major contributor to age-related decline or diseases
furthermore, weight loss of 5% to 19% of body weight, depending on the agent, has been documented
In line with this, overexpression of wildtype METLL16 enhanced the expression of CBS with 3UTR-1 mutation but not with 3UTR-2 or 3UTR-3 mutation, further confirming the importance of these two sites in controlling CBS expression (Fig
Tirzepatide: The Leading Choice Mounjaro and Zepbound, brand names for Tirzepatide, have become the preferred options in the realm of weight loss